Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF


1 μg/lane of Recombinant Human ErbB2 Fc Chimera was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing major bands at 125-130 kDa and 220-250 kDa, more
Recombinant human ErB2 / Her2 (1129-ER) blocks anti-ErbB2 mediated inhibition of SK-BR-3 human breast cancer proliferation. The ED50 for this effect is 0.3-1.2 µg/mL in the presence of 0.6 µg/mL Anti-Human ErbB2/Her2 more

Product Details

Reactivity HuSpecies Glossary
Applications Bioactivity

Order Details

View Available Formulations
Catalog# & Formulation Size Price

Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF Summary

Details of Functionality
Measured by its ability to block anti-ErbB2 mediated inhibition of SK‑BR‑3 human breast cancer cell proliferation. Brodowicz, T. et al. (1997) Int. J. Cancer 73:875. The ED50 for this effect is 0.3-1.2 μg/mL in the presence of 0.6 µg/mL Anti-Human ErbB2/Her2 Monoclonal Antibody (Trastuzumab, Catalog # MAB9589).
Mouse myeloma cell line, NS0-derived human ErbB2/Her2 protein
Human Erb B2
Accession # NP_004439
6 His-tag
N-terminus C-terminus
Accession #
N-terminal Sequence
Structure / Form
Disulfide-linked homodimer
Protein/Peptide Type
Recombinant Proteins
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.


  • Bioactivity
Theoretical MW
96.8 kDa (monomer).
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
125-130 kDa, reducing conditions
220-250 kDa, non-reducing conditions
Read Publications using
1129-ER in the following applications:

Packaging, Storage & Formulations

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS.
>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS.


This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF

  • CD340 antigen
  • CD340
  • c-erb B2/neu protein
  • EC 2.7.10
  • EGFR2
  • ErbB2
  • HER2
  • HER-2
  • HER2EC
  • herstatin
  • Metastatic lymph node gene 19 protein
  • MLN 19
  • MLN19
  • Neu Oncogene
  • NEUHER-2/neu
  • neuroblastoma/glioblastoma derived oncogene homolog
  • NGL
  • p185erbB2
  • Proto-oncogene c-ErbB-2
  • Proto-oncogene Neu
  • receptor tyrosine-protein kinase erbB-2
  • TKR1
  • Tyrosine kinase-type cell surface receptor HER2
  • v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2(neuro/glioblastoma derived oncogene homolog)
  • v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastomaderived oncogene homolog (avian)


ErbB2, also called Neu and Her2 (human epidermal growth factor receptor 2), is a type I membrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. ErbB2 is widely expressed in epithelial cells and has also been found to be over-expressed in a large number of breast carcinomas. Among ErbB family members, ErbB2 is unique in that it has no identified ligands. Rather, ErbB2 heterodimerizes with the other members of the ErbB family (ErbB1 (EGFR), ErbB3, ErbB4) to form higher affinity signaling complexes. Because ErbB3 contains a defective kinase domain, the kinase domain of ErbB2 is responsible for initiating the tyrosine phosphorylation signal through the heterodimeric receptor. It has been found that a discrete three amino acid signal in the ErbB3 cytoplasmic domain is critical for transactivation of ErbB2. Interestingly, this same three amino acid signal has also been found in ErbB1 and ErbB4. Phosphoinositide 3-kinase has been shown to play a role in ErbB2 signal transduction. The cytoplasmic domain of ErbB2 has been shown to associate with beta-catenin and plakoglobin. Human ErbB2 consists of 1255 amino acids (aa) with a 21 aa signal sequence, a 631 aa extracellular domain, a 23 aa transmembrane region, and a 580 aa cytoplasmic domain. ErbB2 can be shed from the cell surface by proteolytic cleavage by an unidentified protease. ErbB2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation (1-10).

  1. Coussens, L. et. al. (1985) Science 230:1132.
  2. Yamamoto, T. et. al. (1986) Nature 319:230.
  3. Kanai, Y. et. al. (1995) Biochem. Biophys. Res. Commun. 208:1067.
  4. Codony-Servat, J. et. al. (1999) Cancer Res. 59:1196.
  5. Carraway, K.L. 3rd et. al.  (1994) J. Biol. Chem. 269:14303.
  6. Emkey, R. and C.R. Kahn (1997) J. Biol. Chem. 272:31172.
  7. Schaefer, G. et. al. (1999) J. Biol. Chem. 274:859.
  8. Schlessinger, J. (2000) Cell 103:211.
  9. Hellyer, N.J. et. al. (2001) J. Biol. Chem. 276:42153.
  10. Daly, R.J. (1999) Growth Factors 16:255.

Customers Who Viewed This Item Also Viewed...

Species: Hu
Applications: CyTOF-ready, ELISA(Cap), ELISA(Det), ELISA(Sta), Flow, ICC, IHC, IP, Simple Western, WB
Species: Hu
Applications: ICC, IHC, Simple Western, WB
Species: Av, Bv, Ma, Hu, Mu, Pm, Rt
Applications: IF, IHC, IHC-Fr, IHC-P, WB
Species: Hu, Mu, Rt, Xp(-), Ye
Applications: CyTOF-ready, ELISA, Flow-IC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
Species: Hu
Applications: BA
Species: Hu
Applications: ELISA, AP, PA, PAGE, WB
Species: Hu
Applications: ICC/IF, IHC, IHC-P
Species: Hu, Mu, Rt
Applications: CyTOF-ready, IHC, ICFlow, Simple Western, WB
Species: Hu
Applications: CyTOF-ready, ELISA(Cap), ELISA(Det), ELISA(Sta), Flow, Neut
Species: Hu, Mu, Rt
Applications: ICC/IF, IHC, IHC-P, IP, WB
Species: Hu
Applications: ELISA
Species: Ca, Hu, Mu, Rt
Applications: IHC, IHC-P, IP, WB
Species: Bv, Dr, Hu, Mu
Applications: ChIP, ELISA, Flow-IC, Flow, IB, ICC/IF, IHC, IHC-Fr, IHC-P, IP, PLA, S-ELISA, Simple Western, WB
Species: Hu, Pm, Mu, Rt
Applications: Flow, ICC/IF, IHC, IHC-P, WB
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-P, WB
Species: Hu, Mu
Applications: ICC/IF, WB

Publications for ErbB2/Her2 (1129-ER)(54)

We have publications tested in 5 confirmed species: Human, Mouse, Drosophila, Hamster, N/A.

We have publications tested in 13 applications: Bioassay, CAR-T (Bioassay), CAR-T (Flow Cytometry), Direct ELISA, Dot Blot, ELISA (Capture), ELISA (Standard), ELISA Capture, Flow Cytometry, ICC, Surface Plasmon Resonance, Surface Plasmon Resonance (SPR, Western Blot.

Filter By Application
CAR-T (Bioassay)
CAR-T (Flow Cytometry)
Direct ELISA
Dot Blot
ELISA (Capture)
ELISA (Standard)
ELISA Capture
Flow Cytometry
Surface Plasmon Resonance
Surface Plasmon Resonance (SPR
Western Blot
All Applications
Filter By Species
All Species
Showing Publications 1 - 10 of 54. Show All 54 Publications.
Publications using 1129-ER Applications Species
Mez?si-Csaplár, M;Szö?r, Á;Vereb, G; CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells Cancers 2023-06-07 [PMID: 37370693] (Flow Cytometry, Human) Flow Cytometry Human
M Po?niak, D ?ukowska, A G?daj, MA Krzy?cik, N Por?bska, M Zakrzewska, J Otlewski, ? Opali?ski The Significance of Cell Surface N-Glycosylation for Internalization and Potency of Cytotoxic Conjugates Targeting Receptor Tyrosine Kinases International Journal of Molecular Sciences, 2022-07-31;23(15):. 2022-07-31 [PMID: 35955648] (Bioassay, Human) Bioassay Human
N Hebbar, R Epperly, A Vaidya, U Thanekar, SE Moore, M Umeda, J Ma, SL Patil, D Langfitt, S Huang, C Cheng, JM Klco, S Gottschalk, MP Velasquez CAR T cells redirected to cell surface GRP78 display robust anti-acute myeloid leukemia activity and do not target hematopoietic progenitor cells Nature Communications, 2022-01-31;13(1):587. 2022-01-31 [PMID: 35102167] (Flow Cytometry, Human) Flow Cytometry Human
J Garousi, H Ding, E von Wittin, T Xu, A Vorobyeva, M Oroujeni, A Orlova, S Hober, T Gräslund, V Tolmachev Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein Pharmaceutics, 2021-11-03;13(11):. 2021-11-03 [PMID: 34834262] (Bioassay, Human) Bioassay Human
N Stoup, M Liberelle, C Schulz, S Cavdarli, R Vasseur, R Magnez, F Lahdaoui, N Skrypek, F Peretti, F Frénois, X Thuru, P Melnyk, N Renault, N Jonckheere, N Lebègue, I Van Seunin The EGF Domains of MUC4 Oncomucin Mediate HER2 Binding Affinity and Promote Pancreatic Cancer Cell Tumorigenesis Cancers, 2021-11-16;13(22):. 2021-11-16 [PMID: 34830899] (Bioassay, Human) Bioassay Human
R Chidiac, M Abedin, G Macleod, A Yang, PE Thibeault, LL Blazer, JJ Adams, L Zhang, H Roehrich, HN Jo, S Seshagiri, SS Sidhu, HJ Junge, S Angers A Norrin/Wnt surrogate antibody stimulates endothelial cell barrier function and rescues retinopathy Embo Molecular Medicine, 2021-06-09;0(0):e13977. 2021-06-09 [PMID: 34105895] (Bioassay, Human) Bioassay Human
H Ding, T Xu, J Zhang, V Tolmachev, M Oroujeni, A Orlova, T Gräslund, A Vorobyeva Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution Pharmaceutics, 2021-03-23;13(3):. 2021-03-23 [PMID: 33806887] (Surface Plasmon Resonance, Human) Surface Plasmon Resonance Human
SF Yuan, SM Brooks, AW Nguyen, WL Lin, TG Johnston, JA Maynard, A Nelson, HS Alper Bioproduced Proteins On Demand (Bio-POD) in hydrogels using Pichia pastoris Bioactive materials, 2021-01-27;6(8):2390-2399. 2021-01-27 [PMID: 33553823] (Bioassay, Hamster) Bioassay Hamster
T Xu, H Ding, A Vorobyeva, M Oroujeni, A Orlova, V Tolmachev, T Gräslund Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model Cancers, 2020-12-30;13(1):. 2020-12-30 [PMID: 33396753] (Bioassay, Human) Bioassay Human
RA Youness, AZ Gad, K Sanber, YJ Ahn, GJ Lee, E Khallaf, HM Hafez, AA Motaal, N Ahmed, MZ Gad Targeting hydrogen sulphide signaling in breast cancer Journal of advanced research, 2020-07-16;27(0):177-190. 2020-07-16 [PMID: 33318876] (Bioassay, Human) Bioassay Human
Show All 54 Publications.

Reviews for ErbB2/Her2 (1129-ER) (0)

There are no reviews for ErbB2/Her2 (1129-ER). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for ErbB2/Her2 (1129-ER). (Showing 1 - 1 of 1 FAQs).

  1. I am interested in getting antibodies for HER that would work in flow cytometry. Could you recommend some choices?
    • A list of our ErbB2 antibodies validated for use in flow cytometry can be found here /productsearch/HER2#fq=common_name%3A%22ErbB2%2FHER2%22&fq=category%3A%22Primary%20Antibodies%22&fq=applications%3A%22Flow%20Cytometry%22

Additional ErbB2/Her2 Products

Bioinformatics Tool for ErbB2/Her2 (1129-ER)

Discover related pathways, diseases and genes to ErbB2/Her2 (1129-ER). Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
Visit Tool

Diseases for ErbB2/Her2 (1129-ER)

Discover more about diseases related to ErbB2/Her2 (1129-ER).

Pathways for ErbB2/Her2 (1129-ER)

View related products by pathway.

PTMs for ErbB2/Her2 (1129-ER)

Learn more about PTMs related to ErbB2/Her2 (1129-ER).

Blogs on ErbB2/Her2.

Unlocking the Potential of Biosimilars in Immuno-Oncology
By Jennifer Jones, M.S.Biosimilar Antibodies: Imitation Meets InnovationIn the ever-evolving medical landscape, a new class of pharmaceuticals is emerging as a game-changer, poised to transform the way we approach...  Read full blog post.

NPC1: A Potential Target For Triple-Negative Breast Cancer
By Natalia Gurule, PhD Breast Cancer is a Heterogeneous DiseaseBreast cancer is the most frequently identified malignancy in women, accounting for 30% of diagnosed cases of cancer in women in the US annuall...  Read full blog post.

Hypoxia-Dependent CAR Stabilizing Construct in T cells Improves Solid Tumor Targeting and Efficacy
By Victoria Osinski, PhDDespite advances in the development of cancer immunotherapies, those specifically targeting tumors still remains limited. Currently, there is great interest in utilizing chimeric antigen rece...  Read full blog post.

Harnessing Natural Killer Cell Activity for Anti-Tumor Immunotherapy
By Victoria Osinski, PhDWhat’s “Natural” About Natural Killer (NK) Cells?For immunologists, the term cytotoxicity often conjures up images of an army of antigen specific CD8+ T cells deploying to ...  Read full blog post.

Customers Who Bought This Also Bought

Contact Information

Product PDFs


Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.


Review this Product

Be the first to review our Recombinant Human ErbB2/Her2 Fc Chimera Protein, CF and receive a gift card or discount.


Gene Symbol ERBB2